Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT05265962 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Start date: December 1, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to observe and evaluate the efficacy and safety of Decitabine plus Penpulimab as second-line therapy for advanced esophageal squamous cell carcinoma treated with PD-1 blockade

NCT ID: NCT05246228 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of the Skin

Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy

HR-cSCC
Start date: March 1, 2022
Phase:
Study type: Observational

Treatment with adjuvant radiotherapy modulates immune system in many diseases as witnessed by dynamic changes of humoral and cellular immunity. Moreover, the persistent lymphopenia after radiation therapy is a negative prognostic factor. This study is aimed to explore the changes in immune-cell populations during radiotherapy given as adjuvant treatment for high-risk cutaneous squamous cell carcinomas and to correlate them with patient's outcome.

NCT ID: NCT05244798 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

Start date: November 1, 2022
Phase: Phase 3
Study type: Interventional

Comparative analysis of patients with resectable locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy combined sintilimab versus neoadjuvant chemoradiotherapy.

NCT ID: NCT05189184 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma

HNSCC
Start date: March 30, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, open-labelled study to evaluate the efficacy and safety of Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Metastatic or Recurrent, UnresectableHead and Neck Squamous Cell Carcinoma. The objective response rate (ORR) will be evaluated as the primary endpoints.

NCT ID: NCT05136768 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)

LM-HNSCC
Start date: December 2021
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of combination of Sintilimab and SBRT on the basis of platinum-containing chemotherapy as the first-line treatment of limited metastatic head and neck squamous cell carcinoma (LM-HNSCC).

NCT ID: NCT05103501 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinomas

Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy

SINCERE
Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of esophageal squamous cell carcinoma patients nonresponding to initial neoadjuvant chemoradiotherapy. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy in the adjuvant treatment of esophageal squamous cell carcinoma after surgery.

NCT ID: NCT05065346 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC

Start date: March 2025
Phase: N/A
Study type: Interventional

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device (DaRT) as a treatment prior to additional radiation or chemo therapy.

NCT ID: NCT05043688 Not yet recruiting - Clinical trials for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

A Trial Of Neoadjuvant Chemotherapy or Radiochemotherapy With Or Without SHR-1210 In Patients With Resectable ESCC.

Start date: September 14, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the effectiveness and safety of neoadjuvant immune combined chemotherapy or radiochemotherapy compared with traditional neoadjuvant radiochemotherapy in patients with locally advanced Esophageal Squamous Cell Carcinoma.

NCT ID: NCT05039606 Not yet recruiting - Clinical trials for Head and Neck Squamous Carcinoma

Clinical Study of Radiotherapy Combined With Nedaplatin Contrast and Cisplatin for the Treatment of Locally Advanced Head and Neck Squamous Carcinoma

Start date: September 2021
Phase: Phase 2
Study type: Interventional

This study was designed as a prospective, multicenter and randomized clinical study of radiotherapy combined with Nedaplatin contrast and cisplatin for local advanced head and neck squamous SCC, aiming to explore the efficacy, safety and long-term efficacy of this trial and control groups and provide some evidence for the selection of clinical treatment options.

NCT ID: NCT05024019 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

Start date: August 21, 2021
Phase: Phase 2
Study type: Interventional

This study is a prospective, open label, multicenter, randomized controlled clinical trial. The main purpose of the study is to evaluate the efficacy and safety of nimotuzumab combined with concurrent radiotherapy versus radiotherapy alone in high-risk patients with HNSCC not suitable for cisplatin after surgery. The subjects were randomly divided into study group (nimotuzumab combined with concurrent radiotherapy) and control group (radiotherapy alone) by 1∶1 stratified random method.